

Special Issue

The Current Landscape of Nucleic-Acid-Based Drugs

Message from the Guest Editor

To achieve a better understanding and exploration of the nucleic-acid-based therapeutics and nanostructures as drug carriers, papers addressing the following aspects are welcome (note that we use the term 'nucleic-acid-based drugs' to include all nucleic-acid-based approaches): 1) new nucleic acid therapeutics, platforms for the delivery of nucleic-acid therapeutics, the rationale and key technological aspects for improving their therapeutic effectiveness, and the technologies facilitating their clinical translation. 2) Studies on various DNA nanostructure-based drug delivery systems—their design strategies; the targeting and stimuli-responsive mechanisms of the platforms; their drug release behaviors; and their disease therapeutic effects.

Guest Editor

Dr. Zhenbao Liu

Xiangya School of Pharmaceutical Sciences, Central South University, Changsha, China

Deadline for manuscript submissions

closed (31 May 2024)



Molecules

an Open Access Journal
by MDPI

Impact Factor 4.2
CiteScore 7.4
Indexed in PubMed



mdpi.com/si/108339

Molecules

MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
molecules@mdpi.com

[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)





Molecules

an Open Access Journal
by MDPI

Impact Factor 4.2
CiteScore 7.4
Indexed in PubMed



[mdpi.com/journal/
molecules](https://mdpi.com/journal/molecules)



About the Journal

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 25th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarinLit, AGRIS, and other databases.

Journal Rank:

JCR - Q2 (Chemistry, Multidisciplinary) / CiteScore - Q1 (Chemistry (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2024).